Weizmann Institute of Science:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Weizmann Institute of Science - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11523
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Weizmann Institute of Science (WIS) is a research institute that offers research activities in the field of natural and exact sciences. The institute provides programs that include graduate programs, post graduate programs, scientific research, academic affairs, science education, research and development. It carries out research and education through its different departments and faculties in the field of biology, biochemistry, physics, chemistry, mathematics and computer science. WIS also offers research services through division of research services, biological services unit and veterinary resources among others. The institute also offers research activities in the field of brain research, cancer research, plant sciences, nanotechnology, genetics and photosynthesis. It also provides graduate studies and post gradate studies. The institute has collaboration with the institute’s scientists, educators, administrators and volunteers for research and science education. WIS is headquartered in Rehovot, Israel.

Weizmann Institute of Science – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Weizmann Institute of Science, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Weizmann Institute of Science, Medical Devices Deals, 2012 to YTD 2018 9
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 12
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 13
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 14
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 15
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 16
XL-protein Enters into Collaboration Agreement with Yeda Research 17
Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 18
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 19
Licensing Agreements 20
Stem Cell Medicine Enters into Licensing Agreement with Ramot at Tel Aviv University and Yeda Research and Development 20
TxCell Exercises Option for Licensing Agreement with Yeda Research and Development 21
Tikcro Technologies Amends Research and Licensing Agreement with Yeda Research and Development 22
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 23
XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 24
miCure Therapeutics Enters into Licensing Agreement with Yeda Research 26
Merck Enters into Licensing Agreement with Weizmann Institute of Science 27
PsychoGenics Enters into Licensing Agreement with Yeda Research and Development 28
Weizmann Institute of Science – Key Competitors 29
Weizmann Institute of Science – Key Employees 30
Weizmann Institute of Science – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Government and Public Interest 32
Sep 12, 2018: A new approach to identifying “signposts” on cancer cells may help immune cells eliminate the disease 32
Jul 25, 2018: Combined Approach Offers Hope to Lung Cancer Patients Who Become Resistant to Drugs 34
May 17, 2017: Rare Genetic Defect May Lead to Cancer Drug 36
Jan 26, 2017: Weizmann Institute of Science: Programmed Proteins Might Help Prevent Malaria 37
Product News 38
Jan 23, 2017: RondinX Expands its Microbiome Computational Platform for Drug Development with a Unified Reference Range of Bacterial Dynamics Based on Database of 1,400 Healthy Individuals 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Key Facts 2
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Weizmann Institute of Science, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Weizmann Institute of Science, Deals By Therapy Area, 2012 to YTD 2018 8
Weizmann Institute of Science, Medical Devices Deals, 2012 to YTD 2018 9
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Therapix Biosciences Enters into Agreement with Weizmann Institute and Tel Aviv Sourasky 12
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 13
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 14
Galmed Pharma Enters into Research Agreement with Yeda Research and Development 15
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 16
XL-protein Enters into Collaboration Agreement with Yeda Research 17
Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 18
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 19
Stem Cell Medicine Enters into Licensing Agreement with Ramot at Tel Aviv University and Yeda Research and Development 20
TxCell Exercises Option for Licensing Agreement with Yeda Research and Development 21
Tikcro Technologies Amends Research and Licensing Agreement with Yeda Research and Development 22
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 23
XTL Biopharma Amends Licensing Agreement with Yeda Research for hCDR1 24
miCure Therapeutics Enters into Licensing Agreement with Yeda Research 26
Merck Enters into Licensing Agreement with Weizmann Institute of Science 27
PsychoGenics Enters into Licensing Agreement with Yeda Research and Development 28
Weizmann Institute of Science, Key Competitors 29
Weizmann Institute of Science, Key Employees 30
Weizmann Institute of Science, Subsidiaries 31

List of Figures
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Weizmann Institute of Science, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Weizmann Institute of Science, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Weizmann Institute of Science:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Waters Corporation:企業の戦略・SWOT・財務情報
    Waters Corporation - Strategy, SWOT and Corporate Finance Report Summary Waters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dana-Farber Cancer Institute Inc-医療機器分野:企業M&A・提携分析
    Summary Dana-Farber Cancer Institute Inc (Dana-Farber), formerly Sidney Farber Cancer Center is a cancer research center that offers treatment for different types of cancers. The center offers adults and children with various treatment options and also focuses on diagnosis, treatment, cure, and prev …
  • Astron Corp Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corp Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • National Surgical Hospitals Inc-製薬・医療分野:企業M&A・提携分析
    Summary National Surgical Hospitals Inc (NSH) is a healthcare organization that owns, operates and manages surgical facilities. The organization’s management services include operational, clinical, information services, managed care services, legal and compliance services, human resource services, s …
  • JinkoSolar Holding Co Ltd (JKS)-エネルギー分野:企業M&A・提携分析
    Summary JinkoSolar Holding Co., Ltd. (JinkoSolar) is a manufacturer of solar products. The company manufactures and markets solar power products such as silicon ingots, silicon wafers, solar PV cells, and monocrystalline and multicrystalline photovoltaic (PV) panels. JinkoSolar distributes the solar …
  • Ontario Municipal Employees Retirement System-エネルギー分野:企業M&A・提携分析
    Summary Ontario Municipal Employees Retirement System (OMERS) offers pension benefits to government employees, beneficiaries, and retirees from diverse sectors such as municipalities, libraries, police and fire departments, schools, and other agencies in Ontario. It is governed by OMERS Sponsors Cor …
  • BWX Technologies Inc (BWXT):電力:M&Aディール及び事業提携情報
    Summary BWX Technologies Inc (BWXT) is a specialty manufacturer of nuclear components. It designs, engineers, and manufactures precision naval nuclear components, reactors, and nuclear fuel for the US Government. The company also provides special nuclear materials processing and environmental site r …
  • Sime Darby Bhd (SIME):電力:M&Aディール及び事業提携情報
    Summary Sime Darby Bhd (Sime Darby) is a trading and logistics company. It provides diversified products and services through its subsidiaries, affiliates, and joint ventures. The company cultivates oil palm, rubber and sugarcane; rears cattle; and produces oil and fats. It also imports, assembles, …
  • SP Transmission plc:企業の戦略的SWOT分析
    SP Transmission plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • KPMG International Coop:企業の戦略的SWOT分析
    KPMG International Coop - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • MOL Hungarian Oil and Gas PLC (MOL):石油・ガス:M&Aディール及び事業提携情報
    Summary MOL Hungarian Oil and Gas PLC (MOL) is an integrated oil and gas company. It explores for, develops and produces crude oil, natural gas and other gas products. The company refines, transports and stores crude oil; markets crude oil products on wholesale and retail basis, and produces and sel …
  • Lincoln Electric System:企業の発電所・SWOT分析2018
    Lincoln Electric System - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Carlisle Companies Incorporated:戦略・SWOT・企業財務分析
    Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report Summary Carlisle Companies Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Probiodrug AG (PBD):企業の財務・戦略的SWOT分析
    Summary Probiodrug AG (Probiodrug) is a clinical stage biopharmaceutical company that conducts research and development of new medicines for the treatment of Alzheimer’s disease. The company provides three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a smal …
  • BioMarin Pharmaceutical Inc (BMRN):医療機器:M&Aディール及び事業提携情報
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasi …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Yangarra Resources Ltd (YGR):企業の財務・戦略的SWOT分析
    Summary Yangarra Resources Ltd (Yangarra) is an oil and gas company that explores, develops and produces oil and natural gas resources. It owns and operates oil and gas properties in Medicine Hat, Central Alberta, and Jaslan. It has infrastructure and land holdings. Central Alberta productive zones …
  • Pernix Therapeutics Holdings Inc (PTX):医療機器:M&Aディール及び事業提携情報
    Summary Pernix Therapeutics Holdings Inc (Pernix Therapeutics) is a specialty pharmaceutical company that discovers, develops, and markets generic pharmaceutical products. The company’s portfolio encompasses a fixed dose combination product prescribed to treat acute migraine; an extended-release (XR …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆